Annals of Hepatology (Sep 2021)
P-111 FREQUENCY OF LIVER STEATOSIS AND FIBROSIS DETERMINED BY FIBROSCAN AND CAP IN A SCREENING PROGRAM
Abstract
Introduction: Nonalcoholic fatty liver disease represents a worldwide public health problem, in Latin America a prevalence of around 30% is estimated, however in Peru we do not have large epidemiological studies about this. Objectives: To evaluate the frequency of liver steatosis determined by CAP (Controlled Attenuation Parameter) and liver fibrosis by hepatic elastography in a population of patients who participated in a screening campaign. Material and Methods: Descriptive and cross-sectional study. During the period September-December 2019, the ALEH Screening Fibroscan program was carried out in 4 reference hospitals in Lima and Callao. Patients were evaluated with a Fibroscan 530 device with M and XL probes. Those examinations that met the quality parameters were included for the study: 10 valid measurements, IQR <30% for liver stiffness, IQR <40 dB / m for CAP. The study population was people aged 18 and older who voluntarily attended the screening campaigns. Results: 1978 patients were included, with an average age of 54.22 +/- 14.36 years, the distribution by sex was 1342 women (67.8%) and 636 men (32.2%). The distribution according to the degree of liver steatosis determined by CAP was S0: 1198 (60.6%), S1: 335 (16.9%), S2: 59 (3%), S3: 386 (19.5%). The distribution according to the degree of fibrosis was F0-1: 1662 (84%), F2: 97 (4.9%), F3: 98 (5%), F4: 121 (6.1%). Conclusions: In the studied population a frequency of hepatic steatosis of 39.4% and advanced hepatic fibrosis of 11.1% was found.